<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Tolonen JP</submitter><funding>Henry Smith Charity</funding><funding>Sigrid Juséliuksen Säätiö</funding><funding>Stiftelsen Alma och K. A. Snellman Säätiö</funding><funding>Medical Research Council</funding><funding>Ataxia UK</funding><funding>University of Oxford</funding><funding>Lastentautien Tutkimussäätiö</funding><funding>Wellcome Trust</funding><funding>Orionin Tutkimussäätiö</funding><funding>H2020 Excellent Science</funding><funding>Parkinson's UK</funding><pagination>141-151</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10952845</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>39(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The ITPR1 gene encodes the inositol 1,4,5-trisphosphate (IP&lt;sub>3&lt;/sub> ) receptor type 1 (IP&lt;sub>3&lt;/sub> R1), a critical player in cerebellar intracellular calcium signaling. Pathogenic missense variants in ITPR1 cause congenital spinocerebellar ataxia type 29 (SCA29), Gillespie syndrome (GLSP), and severe pontine/cerebellar hypoplasia. The pathophysiological basis of the different phenotypes is poorly understood.&lt;h4>Objectives&lt;/h4>We aimed to identify novel SCA29 and GLSP cases to define core phenotypes, describe the spectrum of missense variation across ITPR1, standardize the ITPR1 variant nomenclature, and investigate disease progression in relation to cerebellar atrophy.&lt;h4>Methods&lt;/h4>Cases were identified using next-generation sequencing through the Deciphering De</pubmed_abstract><journal>Movement disorders : official journal of the Movement Disorder Society</journal><pubmed_title>Detailed Analysis of ITPR1 Missense Variants Guides Diagnostics and Therapeutic Design.</pubmed_title><pmcid>PMC10952845</pmcid><funding_grant_id>101023312</funding_grant_id><funding_grant_id>223521/Z/21/Z</funding_grant_id><funding_grant_id>GN2063</funding_grant_id><funding_grant_id>331436</funding_grant_id><funding_grant_id>356676</funding_grant_id><funding_grant_id>MR/V007068/1</funding_grant_id><funding_grant_id>J-1403</funding_grant_id><pubmed_authors>Moore AP</pubmed_authors><pubmed_authors>Williams J</pubmed_authors><pubmed_authors>Uusimaa J</pubmed_authors><pubmed_authors>Stewart H</pubmed_authors><pubmed_authors>Jones WD</pubmed_authors><pubmed_authors>Shears D</pubmed_authors><pubmed_authors>Shanks ME</pubmed_authors><pubmed_authors>Genomics England Research Consortium</pubmed_authors><pubmed_authors>Lerman-Sagie T</pubmed_authors><pubmed_authors>Houlden H</pubmed_authors><pubmed_authors>Jarvis J</pubmed_authors><pubmed_authors>Hadjivassiliou M</pubmed_authors><pubmed_authors>Nemeth AH</pubmed_authors><pubmed_authors>Lynch SA</pubmed_authors><pubmed_authors>Harrison RE</pubmed_authors><pubmed_authors>Znaczko A</pubmed_authors><pubmed_authors>Martinez Albaladejo I</pubmed_authors><pubmed_authors>McGowan S</pubmed_authors><pubmed_authors>Parolin Schnekenberg R</pubmed_authors><pubmed_authors>Granath K</pubmed_authors><pubmed_authors>Shaw-Smith C</pubmed_authors><pubmed_authors>Kneen R</pubmed_authors><pubmed_authors>McCann E</pubmed_authors><pubmed_authors>Tofaris GK</pubmed_authors><pubmed_authors>Tolonen JP</pubmed_authors><pubmed_authors>Dabir T</pubmed_authors><pubmed_authors>Ellard S</pubmed_authors><pubmed_authors>Blumkin L</pubmed_authors><pubmed_authors>Jones G</pubmed_authors><pubmed_authors>Becker EBE</pubmed_authors><pubmed_authors>Raskin S</pubmed_authors><pubmed_authors>Conti H</pubmed_authors><pubmed_authors>McEntagart M</pubmed_authors><pubmed_authors>Kingston H</pubmed_authors><pubmed_authors>Bertoli M</pubmed_authors><pubmed_authors>Clouston P</pubmed_authors><pubmed_authors>Johnson D</pubmed_authors><pubmed_authors>Sims D</pubmed_authors><pubmed_authors>Dixit A</pubmed_authors><pubmed_authors>Joss S</pubmed_authors><pubmed_authors>Sarkar A</pubmed_authors><pubmed_authors>Suri M</pubmed_authors><pubmed_authors>Ceravolo G</pubmed_authors><pubmed_authors>Metcalfe K</pubmed_authors><pubmed_authors>Morrison PJ</pubmed_authors><pubmed_authors>Ponger P</pubmed_authors><pubmed_authors>Elmslie F</pubmed_authors><pubmed_authors>Rankin J</pubmed_authors><pubmed_authors>Blakes AJM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Detailed Analysis of ITPR1 Missense Variants Guides Diagnostics and Therapeutic Design.</name><description>&lt;h4>Background&lt;/h4>The ITPR1 gene encodes the inositol 1,4,5-trisphosphate (IP&lt;sub>3&lt;/sub> ) receptor type 1 (IP&lt;sub>3&lt;/sub> R1), a critical player in cerebellar intracellular calcium signaling. Pathogenic missense variants in ITPR1 cause congenital spinocerebellar ataxia type 29 (SCA29), Gillespie syndrome (GLSP), and severe pontine/cerebellar hypoplasia. The pathophysiological basis of the different phenotypes is poorly understood.&lt;h4>Objectives&lt;/h4>We aimed to identify novel SCA29 and GLSP cases to define core phenotypes, describe the spectrum of missense variation across ITPR1, standardize the ITPR1 variant nomenclature, and investigate disease progression in relation to cerebellar atrophy.&lt;h4>Methods&lt;/h4>Cases were identified using next-generation sequencing through the Deciphering De</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jan</publication><modification>2026-07-15T09:24:29.685Z</modification><creation>2024-11-20T19:04:45.83Z</creation></dates><accession>S-EPMC10952845</accession><cross_references><pubmed>37964426</pubmed><doi>10.1002/mds.29651</doi></cross_references></HashMap>